Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
Ahmed AbdelhakKai AntweilerMarkus C KowarikMakbule SenelJoachim HavlaUwe K ZettlIngo KleiterThomas SkripuletzAxel HaarmannAlexander StahmannAndre HussStefan GingeleMarkus KrumbholzPascal BenkertJens KuhleTim FriedeAlbert C LudolphUlf ZiemannTania KümpfelHayrettin TumaniPublished in: Annals of clinical and translational neurology (2023)
Blood GFAP may help identify pwPPMS at risk of progression. Combination of high GFAP and low NfL levels could distinguish non-active pwPMS with particularly high progression risk.